In the present study, we use a hyperoxia-induced mouse model of BPD and provide a proof-of-principle that cell therapy with c-KIT+FOXF1+ EPCs (generated from pluripotent embryonic stem cells in vitro) can improve neonatal angiogenesis and alveolarization in the mouse BPD model. Here, KIT is linked to bronchopulmonary dysplasia.